Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.
Florian ClatotAnne PerdrixLudivine BeaussireJustine LequesneChristelle LévyGeorge EmileMichael BubenheimSigrid LacailleCéline CalbrixLaetitia AugustoCécile GuillemetCristina AlexandruMaxime FontanillesDavid SefriouiLucie BurelSabine GuénotDoriane RichardNasrin Sarafan-VasseurFrédéric Di FiorePublished in: Breast cancer research : BCR (2020)
ClinicalTrials.gov, NCT02473120. Registered 16 June 2015-retrospectively registered after one inclusion (first inclusion 1 June 2015).